INHIBITION OF SKIN CARCINOMAS BUT NOT PAPILLOMAS BY SPHINGOSINE, N-METHYLSPHINGOSINE, AND N-ACETYLSPHINGOSINE

Citation
Df. Birt et al., INHIBITION OF SKIN CARCINOMAS BUT NOT PAPILLOMAS BY SPHINGOSINE, N-METHYLSPHINGOSINE, AND N-ACETYLSPHINGOSINE, Nutrition and cancer, 31(2), 1998, pp. 119-126
Citations number
26
Categorie Soggetti
Nutrition & Dietetics",Oncology
Journal title
ISSN journal
01635581
Volume
31
Issue
2
Year of publication
1998
Pages
119 - 126
Database
ISI
SICI code
0163-5581(1998)31:2<119:IOSCBN>2.0.ZU;2-F
Abstract
The sphingoid base backbones of sphingolipids are highly bioactive com pounds that affect cell growth, differentiation, diverse cell behavior s, and programmed cell death. Therefore, the efficacy of sphingosine ( SPH) and the analogs N-acetylsphingosine (NAS), N-methylsphingosine (N MS), octylamine (OCT), and sterylamine (STR) in the prevention of skin cancer was assessed in female Sencar mice by measuring effects on the induction of epidermal ornithine decarboxylase (ODC) activity and hyp erplasia by 12-O-tetradecanoylphorbol-13-acetate (TPA) and effects on the induction of skin tumors by 7,12-dimethylbenz[a]anthracene (DMBA) and TPA. ODC was measured in the shaved dorsal skin of mice treated to pically with 0.05-20 mu mol of these compounds 30 minutes before appli cation of 8.5 nmol of TPA in 0.2 mi of acetone. ODC activity was inhib ited by greater than or equal to 5 mu mol of SPH and STR, greater than or equal to 10 mu mol of NAS and NMS, and 20 mu mol of OCT. In contra st the induction of hyperplasia was not inhibited by application of th ese compounds 30 minutes before TPA. Two carcinogenesis studies were c onducted with 10 nmol of DMBA as the initiator and 3.2 nmol of TPA (2x /wk for 15 wk) as the promoter. In the first study, NAS, NMS, OCT, and STR (0.05 and 0.5 mu mol) were applied before each TPA application. P apilloma incidence and multiplicity were not inhibited, but NAS (0.05 mu mol) and NMS (0.05 and 0.50 mu mol) increased cancer-free survival. In the second experiment, SPH, NAS, and NMS (0.05 and 0.5 mu mol) wer e applied 30 minutes before each TPA treatment and twice weekly for IO weeks after the final TPA treatment. Papilloma incidence and multipli city were not inhibited; however, the proportion of mice without carci noma was increased by both doses of SPH and by 0.5 mu mol of NAS. Thus low doses of sphingolipids that were not effective in inhibiting ODC activity, reducing hyperplasia, or preventing epidermal papilloma deve lopment were, nonetheless, effective in inhibiting carcinoma developme nt.